Hand

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Brussels Stock Exchange, SCI, Public, Private, KBC, VWAP, ARC, Hand, Acceleration, Regulation, DSM-IV codes, CSO, Movement, EUR, Private placement, BCI, Offerings, Public offering, Equity carve-out, Euronext, Issue, Euronext Amsterdam, Security (finance)

The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.

Key Points: 
  • The final number of New Shares placed and the issue price per New Share (the “Issue Price”) will be announced after pricing of the Offerings.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • “It is the Company’s intention to raise gross proceeds of indicatively EUR 15 million from the Offerings, with an up to EUR 5 million upsize option.
  • A separate announcement will be made shortly regarding the Public Offer in France via the PrimaryBid platform and its terms.

ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option

Retrieved on: 
Wednesday, March 20, 2024
Failure, Economy, Brussels Stock Exchange, Exercise, Patient, Risk, European, Intellectual property, Marketing, SCI, Annual, Public, Private, KBC, AFM, Prospectus, Royal Victorian Order, VWAP, ARC, Hand, Acceleration, Part, Research, Classification, Enrollment, Certification, DSM-IV codes, CSO, FDA, Movement, Engineering, EUR, Private placement, BCI, Offerings, Public offering, Market, Issue, Euronext Amsterdam, Probability, Security (finance)

The Issue Price will be determined by the accelerated book-building initiated with institutional investors.

Key Points: 
  • The Issue Price will be determined by the accelerated book-building initiated with institutional investors.
  • The Public Offering will not extent to retail investors located outside of France.
  • The New Shares will be issued from the Company’s authorized capital under exclusion of the existing shareholders’ pre-emptive rights.
  • It is the Company’s intention to raise gross proceeds of approximately €15.0 million from the Offerings, with an up to €5 million upsize option.

Meet Your Next Hire at FBLA’s Job & Career Fair in Orlando

Retrieved on: 
Wednesday, March 20, 2024
United States Census Bureau, Organization, Conference, FBLA, Learning, Environment, Partnership, Education, Interview, Orange County Convention Center, Student, Workforce, NLC, Hand, Management

The conference will feature the FBLA Job & Career Fair, co-hosted with OrlandoJobs.com, on Tuesday, June 25 from 10 am to 2 pm at the Orange County Convention Center.

Key Points: 
  • The conference will feature the FBLA Job & Career Fair, co-hosted with OrlandoJobs.com, on Tuesday, June 25 from 10 am to 2 pm at the Orange County Convention Center.
  • Hundreds of college students, FBLA alumni in the workforce, and high school students will attend the FBLA Job & Career Fair with resumes in hand.
  • The registration fee for companies is $695, and the event is free for job candidates to attend.
  • FBLA inspires and prepares students to become community-minded business leaders in a global society through relevant career preparation and leadership experiences.

HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2024 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Tax, The Company, Growth, Conduent, HealthEquity, Acquisition, Table, Nature, HQY, Investment, Depreciation, GAAP, HSA, Eastern Time Zone, Hand, Bank

DRAPER, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced financial results for its fourth quarter and fiscal year ended January 31, 2024.

Key Points: 
  • DRAPER, Utah, March 19, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") custodian, today announced financial results for its fourth quarter and fiscal year ended January 31, 2024.
  • Revenue for the fourth quarter ended January 31, 2024 was $262.4 million, an increase of 12% compared to $233.8 million for the fourth quarter ended January 31, 2023.
  • Adjusted EBITDA was $98.8 million for the fourth quarter ended January 31, 2024, an increase of 34% compared to $73.6 million for the fourth quarter ended January 31, 2023.
  • HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, March 19, 2024 to discuss the fiscal 2024 fourth quarter and year-end results.

XPENG Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Research, Master, Volkswagen Group, Platform, Three Months, Growth, XPENG, Partnership, Volkswagen, Software, ADS, G9, G6, Loss, Advertising, Investment, MPV, Marketing, Hand, Engineering, Total, Video game

Gross margin was 6.2% for the fourth quarter of 2023, compared with 8.7% for the same period of 2022 and negative 2.7% for the third quarter of 2023.

Key Points: 
  • Gross margin was 6.2% for the fourth quarter of 2023, compared with 8.7% for the same period of 2022 and negative 2.7% for the third quarter of 2023.
  • Vehicle margin was 4.1% for the fourth quarter of 2023, compared with 5.7% for the same period of 2022 and negative 6.1% for the third quarter of 2023.
  • Basic and diluted net loss per ADS were both RMB1.51 (US$0.21) for the fourth quarter of 2023, compared with RMB2.74 for the fourth quarter of 2022 and RMB4.49 for the third quarter of 2023.
  • Non-GAAP basic and diluted net loss per ADS were both RMB1.98 (US$0.28) for the fourth quarter of 2023, compared with RMB2.57 for the fourth quarter of 2022 and RMB3.23 for the third quarter of 2023.

Hudson Announces Change of Name to AnorTech Inc.

Retrieved on: 
Tuesday, March 19, 2024
TSX Venture Exchange, CUSIP, Bank statement, CO2, OTC, Aluminium, Hand

The new CUSIP for the Company's common shares will be 03634T104 and the new ISIN number will be CA03634T1049.

Key Points: 
  • The new CUSIP for the Company's common shares will be 03634T104 and the new ISIN number will be CA03634T1049.
  • A new corporate website will also be launched on the same day under the domain www.anortechinc.com .
  • Issued certificates representing common shares of the Company will not be affected by the name change and will not need to be exchanged.
  • The name change does not affect the rights of the Company’s shareholders.

EXL announces $125 million accelerated share repurchase program

Retrieved on: 
Monday, March 18, 2024
EXL, ASR, Share repurchase, Hand, Citibank

NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data analytics and digital operations and solutions company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A.

Key Points: 
  • NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- EXL [NASDAQ: EXLS], a leading data analytics and digital operations and solutions company, today announced that, as part of its capital allocation program, it has entered into an accelerated share repurchase agreement (the “ASR”) with Citibank, N.A.
  • to repurchase $125 million of the company’s common stock.
  • The company plans to fund the repurchase with available cash on hand and/or borrowing from its credit facility.
  • The ASR is a part of the company’s current $500 million stock repurchase program.

MBLY DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Mobileye Global Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MBLY

Retrieved on: 
Monday, March 18, 2024
Titan, Mobileye, Risk, Class, EyeQ, Advertising, Court, Hand, Tobacco

WHAT TO DO NEXT: To join the Mobileye class action, go to https://rosenlegal.com/submit-form/?case_id=21612 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Mobileye class action, go to https://rosenlegal.com/submit-form/?case_id=21612 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

Heidelberg Materials’ Mitchell Cement Plant Hosts Open House Demonstrating State-of-the-Art Packaging System

Retrieved on: 
Monday, March 18, 2024
Element, Growth, HeidelbergCement, Safety, Rock (geology), Hand

Irving, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Heidelberg Materials North America recently hosted customers and other industry partners at its Mitchell, Indiana, cement plant to demonstrate the operation of its rotating packaging system.

Key Points: 
  • Irving, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Heidelberg Materials North America recently hosted customers and other industry partners at its Mitchell, Indiana, cement plant to demonstrate the operation of its rotating packaging system.
  • The 12-spout, automated rotating packaging system can fill a bag per second.
  • The new Mitchell plant has enhanced the support of Heidelberg Materials’ existing customer base in the Midwest while also expanding the company’s reach in the growing cement market.
  • Visit heidelbergmaterials.us to learn more about the Mitchell, Indiana, cement plant.